SCHEMBL585906

SCHEMBL585906

COc1cc(F)cc(CO)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.62
CYP4A11 Q02928 1/20 0.62
DAO P14920 1/20 0.43
EPAS1 Q99814 1/20 0.40
ALDH1A1 P00352 2/20 0.40
FFAR4 Q5NUL3 1/20 0.39
ALKBH1 Q13686 1/20 0.39
MAPT P10636 1/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39
MAOB P27338 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
CALM1 P0DP23 1/20 0.38
AKR1B1 P15121 1/20 0.38
PTGS2 P35354 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1621101 0.84 DAO (0.53) CYP4F2CYP4A11DAOALDH1A1MAPT
SCHEMBL65276 0.84 ALDH1A1 (0.58) CYP4F2CYP4A11DAOALDH1A1MAPT
SCHEMBL23343786 0.84 CYP4F2 (0.46) CYP4F2CYP4A11DAOALDH1A1FFAR4
SCHEMBL14856240 0.83 CYP4F2 (0.44) CYP4F2CYP4A11ALDH1A1FFAR4ALKBH1
SCHEMBL28123040 0.82 ALDH1A1 (0.55) CYP4F2CYP4A11DAOALDH1A1MAPT
SCHEMBL241171 0.81 PTGS2 (0.43) CYP4F2CYP4A11ALDH1A1FFAR4ALKBH1
SCHEMBL16961014 0.80 CYP4F2 (0.59) CYP4F2CYP4A11EPAS1FFAR4MAOB
SCHEMBL7664052 0.79 CYP4F2 (0.44) CYP4F2CYP4A11ALDH1A1FFAR4ALKBH1
SCHEMBL16958198 0.79 CYP4F2 (0.41) CYP4F2CYP4A11ALDH1A1FFAR4ALKBH1
SCHEMBL3685037 0.79 TAAR1 (0.47) CYP4F2CYP4A11ALDH1A1FFAR4GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3664213-B1 ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME LG ENERGY SOLUTION LTD (KR) 2023-09-13 EP claimed
EP-3547414-B1 LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME LG ENERGY SOLUTION LTD (KR) 2023-09-13 EP claimed
US-11495824-B2 Electrolyte for lithium metal battery and lithium metal battery comprising same LG ENERGY SOLUTION, LTD. (KR) 2022-11-08 US claimed
CN-110192294-B Lithium electrode and lithium secondary battery comprising same 株式会社LG新能源 2022-09-20 CN claimed
CN-111033864-B Electrolyte for lithium metal battery and lithium metal battery comprising same 株式会社LG新能源 2022-08-12 CN claimed
US-20200203759-A1 ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME LG CHEM, LTD. (KR) 2020-06-25 US claimed
EP-3664213-A2 ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME LG Chem, Ltd. (KR) 2020-06-10 EP claimed
US-20190319272-A1 LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME LG CHEM, LTD. (KR) 2019-10-17 US claimed
EP-3547414-A2 LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME LG Chem, Ltd. (KR) 2019-10-02 EP claimed
US-12180221-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-12-31 US disclosed
CN-118084801-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-118084800-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-112312913-B Compounds and uses thereof 詹森药业有限公司 2024-03-08 CN disclosed
EP-3547414-B1 LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME LG ENERGY SOLUTION LTD (KR) 2023-09-13 EP disclosed
EP-1963259-A2 SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE AstraZeneca AB (SE) 2008-09-03 EP disclosed
EP-1937632-A1 NOVEL COMPOUNDS Astra Zeneca AB (SE) 2008-07-02 EP disclosed
WO-2007068894-A2 SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2007-06-21 WO disclosed
WO-2007039736-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2007-04-12 WO disclosed
US-6476021-B1 Compounds having cGMP-PDE inhibitory effect MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-11-05 US disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12180221-B2 Compounds and uses thereof NLN, ACHE, CLN6 CYP4F2 1283/4885CYP4A11 898/4885DAO 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.